Expert Interview
Reflecting on the recent FDA approval of REDEMPLO® (plozasiran) from Arrowhead Pharma for the reduction of Triglycerides in Adults with Familial Chylomicronemia Syndrome (FCS).
Ticker(s): ARWRInstitution: Indiana University School of Medicine
Associate Professor of Medicine and interventional cardiologist; Serves as Director of the Cardiac Catheterization Laboratory at IU West and Director of Peripheral Vascular Interventions for IU Cardiology
Manages 1-5 patients with FCS annually
Leads research on advanced endovascular techniques and atherosclerosis treatments, advancing minimally invasive therapies for vascular diseases. specializing in coronary, peripheral arterial, and venous disease management through percutaneous procedures.
Are You Interested In These Questions?
Slingshot Insights Explained
Expert research benefits investors by giving them timely access to unbiased real world perspectives on highly specialized topics. Slingshot Insights' crowdfunded model makes this access available at a fraction of the cost of other expert networks.
Reason
*Slingshot Insights provides access to information, not investment advice. We work to support you and facilitate access to experts; however we are not responsible for monitoring calls for the disclosure of MNPI. You should obtain financial, legal and tax advice from your qualified and licensed advisers before deciding to invest in any security.
